Table_1_First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations.docx (16.81 kB)
Download file

Table_1_First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations.docx

Download (16.81 kB)
dataset
posted on 26.08.2020, 04:48 by Naval Daver, Allyson Price, Christopher B. Benton, Keyur Patel, Weiguo Zhang, Marina Konopleva, Naveen Pemmaraju, Koichi Takahashi, Michael Andreeff, Gautam Borthakur

The prognostics implications of patients with acute myeloid leukemia harboring non-canonical FLT3 is unknown. The use of tyrosine kinase inhibitors in this patient population has not been previously reported. We report successful targeted therapy against non-ITD, non-D835 driver FLT3 alterations in two patient case studies with acute myeloid leukemia.

History